Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 47,619 | 71,543 | 117,164 | 20,620 | 18,752 |
| Marketable Securities | 363,567 | 998,324 | 656,665 | 181,041 | 122,296 |
| Receivables | 59,064 | 41,748 | 55,992 | 25,596 | 14,700 |
| Inventories | 26,487 | 7,296 | 7,124 | 4,373 | 1,923 |
| Other current assets | 3,822 | 4,734 | 33,595 | 5,391 | 5,382 |
| TOTAL | $500,559 | $1,123,645 | $870,540 | $237,021 | $163,053 |
| Non-Current Assets | |||||
| PPE Net | 14,434 | 7,185 | 5,372 | 4,212 | 1,819 |
| Investments And Advances | 0 | 0 | 0 | 6,438 | 8,345 |
| Intangibles | 795,971 | 325,767 | 337,899 | 334,069 | 302,733 |
| Other Non-Current Assets | 51,321 | 38,318 | 46,992 | 89,281 | 125,635 |
| TOTAL | $861,726 | $371,270 | $390,263 | $434,000 | $438,532 |
| Total Assets | $1,362,285 | $1,494,915 | $1,260,803 | $671,021 | $601,585 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 26,433 | 224,529 | 212,910 |
| Accounts payable and accrued liabilities | 3,784 | 2,420 | 4,183 | 2,259 | 2,734 |
| Accrued Expenses | 18,530 | 8,581 | 19,200 | 7,377 | 6,397 |
| Other current liabilities | 39,884 | 2,607 | 29,147 | 4,703 | 5,088 |
| TOTAL | $100,111 | $17,002 | $82,249 | $238,868 | $227,129 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 29,435 | 2,139 | 3,286 | N/A | N/A |
| Other Non-Current Liabilities | 488,051 | 677,744 | 617,640 | 32,365 | 33,166 |
| TOTAL | $552,649 | $710,681 | $617,640 | $32,365 | $33,166 |
| Total Liabilities | $652,760 | $727,683 | $699,889 | $271,233 | $260,295 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 16,612 | 16,505 | 20,445 | 21,204 | 20,920 |
| Common Shares | 16 | 17 | 21 | 21 | 21 |
| Retained earnings | 391,952 | 400,105 | -229,197 | -400,924 | -431,127 |
| Other shareholders' equity | -801 | -216 | -1,024 | 2,486 | 2,743 |
| TOTAL | $709,525 | $767,232 | $560,914 | $399,788 | $341,290 |
| Total Liabilities And Equity | $1,362,285 | $1,494,915 | $1,260,803 | $671,021 | $601,585 |